Atlas Trials

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Clinical trial NCT02520791 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02520791
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Mycosis FungoidesRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRefractory Grade 1 Follicular LymphomaRefractory Grade 2 Follicular LymphomaRefractory Grade 3a Follicular Lymphoma
Start date
2016-09-13
Primary completion
2024-12-18
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.